178 related articles for article (PubMed ID: 8750529)
41. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
42. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors.
Nagai MA; Marques LA; Torloni H; Brentani MM
Oncology; 1993; 50(6):412-7. PubMed ID: 7901824
[TBL] [Abstract][Full Text] [Related]
43. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
44. 11q13 amplification in local recurrence of human primary breast cancer.
Champème MH; Bièche I; Lizard S; Lidereau R
Genes Chromosomes Cancer; 1995 Feb; 12(2):128-33. PubMed ID: 7535085
[TBL] [Abstract][Full Text] [Related]
45. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
46. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
48. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.
Kallioniemi OP; Holli K; Visakorpi T; Koivula T; Helin HH; Isola JJ
Int J Cancer; 1991 Nov; 49(5):650-5. PubMed ID: 1682277
[TBL] [Abstract][Full Text] [Related]
49. ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues.
An HX; Niederacher D; Beckmann MW; Göhring UJ; Scharl A; Picard F; van Roeyen C; Schnürch HG; Bender HG
Int J Cancer; 1995 Oct; 64(5):291-7. PubMed ID: 7591299
[TBL] [Abstract][Full Text] [Related]
50. Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
Joensuu H; Lehtimäki T; Holli K; Elomaa L; Turpeenniemi-Hujanen T; Kataja V; Anttila A; Lundin M; Isola J; Lundin J
JAMA; 2004 Sep; 292(9):1064-73. PubMed ID: 15339900
[TBL] [Abstract][Full Text] [Related]
51. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
52. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Rydén S; Sigurdsson H
Cancer Lett; 1994 Jun; 81(2):137-44. PubMed ID: 7912163
[TBL] [Abstract][Full Text] [Related]
53. ERBB2 oncogene in human breast cancer and its clinical significance.
Révillion F; Bonneterre J; Peyrat JP
Eur J Cancer; 1998 May; 34(6):791-808. PubMed ID: 9797688
[TBL] [Abstract][Full Text] [Related]
54. Gene amplifications in advanced-stage human prostate cancer.
Fournier G; Latil A; Amet Y; Abalain JH; Volant A; Mangin P; Floch HH; Lidereau R
Urol Res; 1995; 22(6):343-7. PubMed ID: 7740653
[TBL] [Abstract][Full Text] [Related]
55. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
[TBL] [Abstract][Full Text] [Related]
56. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
Savinainen KJ; Saramäki OR; Linja MJ; Bratt O; Tammela TL; Isola JJ; Visakorpi T
Am J Pathol; 2002 Jan; 160(1):339-45. PubMed ID: 11786427
[TBL] [Abstract][Full Text] [Related]
57. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
Riou G; Mathieu MC; Barrois M; Le Bihan ML; Ahomadegbe JC; Bénard J; Lê MG
Int J Cancer; 2001 Jul; 95(4):266-70. PubMed ID: 11400121
[TBL] [Abstract][Full Text] [Related]
58. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
[TBL] [Abstract][Full Text] [Related]
59. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.
Vernimmen D; Gueders M; Pisvin S; Delvenne P; Winkler R
Br J Cancer; 2003 Sep; 89(5):899-906. PubMed ID: 12942124
[TBL] [Abstract][Full Text] [Related]
60. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
Bull SB; Ozcelik H; Pinnaduwage D; Blackstein ME; Sutherland DA; Pritchard KI; Tzontcheva AT; Sidlofsky S; Hanna WM; Qizilbash AH; Tweeddale ME; Fine S; McCready DR; Andrulis IL
J Clin Oncol; 2004 Jan; 22(1):86-96. PubMed ID: 14701769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]